- Home
- EQC vs BEAM Comparison
EQC vs BEAM Comparison
Compare EQC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQC
- BEAM
- Stock Information
- Founded
- EQC 1986
- BEAM 2017
- Country
- EQC United States
- BEAM United States
- Employees
- EQC N/A
- BEAM N/A
- Industry
- EQC Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EQC Real Estate
- BEAM Health Care
- Exchange
- EQC Nasdaq
- BEAM Nasdaq
- Market Cap
- EQC 2.2B
- BEAM 1.9B
- IPO Year
- EQC 1986
- BEAM 2020
- Fundamental
- Price
- EQC $1.74
- BEAM $26.85
- Analyst Decision
- EQC
- BEAM Buy
- Analyst Count
- EQC 0
- BEAM 10
- Target Price
- EQC N/A
- BEAM $47.67
- AVG Volume (30 Days)
- EQC 5.4M
- BEAM 1.1M
- Earning Date
- EQC 02-10-2025
- BEAM 11-05-2024
- Dividend Yield
- EQC N/A
- BEAM N/A
- EPS Growth
- EQC N/A
- BEAM N/A
- EPS
- EQC 0.38
- BEAM N/A
- Revenue
- EQC $58,433,000.00
- BEAM $349,643,000.00
- Revenue This Year
- EQC N/A
- BEAM N/A
- Revenue Next Year
- EQC N/A
- BEAM $10.82
- P/E Ratio
- EQC $4.52
- BEAM N/A
- Revenue Growth
- EQC N/A
- BEAM 328.73
- 52 Week Low
- EQC $1.40
- BEAM $20.84
- 52 Week High
- EQC $21.00
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- EQC 4.79
- BEAM 50.06
- Support Level
- EQC $1.66
- BEAM $27.02
- Resistance Level
- EQC $1.76
- BEAM $29.53
- Average True Range (ATR)
- EQC 0.11
- BEAM 2.00
- MACD
- EQC -1.17
- BEAM -0.12
- Stochastic Oscillator
- EQC 1.78
- BEAM 31.29
About EQC Equity Commonwealth of Beneficial Interest
Equity Commonwealth is a real estate investment trust engaged in the acquisition, ownership, and operation of office buildings located throughout the United States. The vast majority of the company's real estate portfolio comprises office assets. These properties are fairly evenly dispersed between many of America's urban markets, notably Washington, Austin, and Denver. Equity Commonwealth derives the vast majority of its income in the form of rental revenue from tenants occupying its offices.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.